CFTR and cystic fibrosis: During the last few years, progress in the development of CFTR modulators has advanced in application from a small CF population with a specific and rare genotype, to a broad population that includes those with one or two copies of the most common F508del CFTR mutation, thus addressing up to 90% of individuals with CF [13,14,15,16].